These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33579809)

  • 1. Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker.
    Chan DL; Ulaner GA; Pattison D; Wyld D; Ladwa R; Kirchner J; Li BT; Lai WV; Pavlakis N; Roach PJ; Bailey DL
    J Nucl Med; 2021 Sep; 62(9):1278-1284. PubMed ID: 33579809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual [
    Chan DL; Hayes AR; Karfis I; Conner A; Furtado O'Mahony L; Mileva M; Bernard E; Roach P; Marin G; Pavlakis N; Schembri G; Gnanasegaran G; Marin C; Vanderlinden B; Navalkissoor S; Caplin ME; Flamen P; Toumpanakis C; Bailey DL
    Br J Cancer; 2023 Feb; 128(4):549-555. PubMed ID: 36434154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Somatostatin Receptor/
    Metser U; Nunez JE; Chan D; Kulanthaivelu R; Murad V; Santiago AT; Singh S
    J Nucl Med; 2024 Oct; 65(10):1591-1596. PubMed ID: 39266292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Chan DL; Hayes AR; Karfis I; Conner A; Mileva M; Bernard E; Schembri G; Navalkissoor S; Gnanasegaran G; Pavlakis N; Marin C; Vanderlinden B; Flamen P; Roach P; Caplin ME; Toumpanakis C; Bailey DL
    J Nucl Med; 2024 Feb; 65(2):185-191. PubMed ID: 38164579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Potential Prognostic Value of Dual-Imaging PET Parameters Based on
    Hou J; Long T; Yang Y; Chen D; Hu S
    Mol Imaging; 2022; 2022():6511179. PubMed ID: 35368455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Quantification of
    Lee H; Nakamoto R; Moore SE; Pantel AR; Eads JR; Aparici CM; Pryma DA
    Acad Radiol; 2022 Sep; 29(9):1308-1316. PubMed ID: 34836776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.
    Chan DL; Pavlakis N; Schembri GP; Bernard EJ; Hsiao E; Hayes A; Barnes T; Diakos C; Khasraw M; Samra J; Eslick E; Roach PJ; Engel A; Clarke SJ; Bailey DL
    Theranostics; 2017; 7(5):1149-1158. PubMed ID: 28435454
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
    Adnan A; Basu S
    J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.
    Hindié E
    Theranostics; 2017; 7(5):1159-1163. PubMed ID: 28435455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Usefulness of
    Rinzivillo M; Partelli S; Prosperi D; Capurso G; Pizzichini P; Iannicelli E; Merola E; Muffatti F; Scopinaro F; Schillaci O; Salgarello M; Falconi M; Delle Fave G; Panzuto F
    Oncologist; 2018 Feb; 23(2):186-192. PubMed ID: 29118267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
    Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
    J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact.
    Hayes AR; Furtado O'Mahony L; Quigley AM; Gnanasegaran G; Caplin ME; Navalkissoor S; Toumpanakis C
    Clin Nucl Med; 2022 Jan; 47(1):26-35. PubMed ID: 34874347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
    Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
    J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous Uptake of 68 Ga-DOTATATE and 18 F-FDG in Initial Diagnosed Neuroendocrine Tumors Patients : Which Patients Are Suitable for Dual-Tracer PET Imaging?
    Zhou Y; Li L; Wang H; Huang HX; Cao D; Ke NW; Su MG; Tian R
    Clin Nucl Med; 2024 Jun; 49(6):516-520. PubMed ID: 38637950
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Binderup T; Knigge U; Johnbeck CB; Loft A; Berthelsen AK; Oturai P; Mortensen J; Federspiel B; Langer SW; Kjaer A
    J Nucl Med; 2021 Jun; 62(6):808-815. PubMed ID: 33067340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms.
    Chan DL; Bernard EJ; Schembri G; Roach PJ; Johnson M; Pavlakis N; Clarke S; Bailey DL
    Neuroendocrinology; 2020; 110(11-12):950-958. PubMed ID: 31711058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Prognostic Value of PET/CT Imaging with Combination of
    Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
    Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients.
    Johnbeck CB; Knigge U; Langer SW; Loft A; Berthelsen AK; Federspiel B; Binderup T; Kjaer A
    J Nucl Med; 2016 Dec; 57(12):1851-1857. PubMed ID: 27469355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.